Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain

References

• International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: IDF; 2015 (7th Edition). http://www.diabetesatlas.org/resources/2015-atlas.html. Accessed June 1, 2016
   Google Scholar
• Inzucchi S, Bergenstal R, Buse J, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care 2015;38:140-9
   PubMed Web of Science ®Google Scholar
• Nottingham Area Prescribing Committee. Treatment algorithm for the management of Type 2 diabetes. Nottingham, UK: NHS; 2016. www.nuh.nhs.uk/handlers/downloads.ashx?id = 62268. Accessed June 1, 2016
   Google Scholar
• Associazione Medici Diabetologi. Standard italiani per la cura del diabete mellito 2014. Italy: Associazione Medici Diabetologi; 2014. p 92. www.standarditaliani.it. Accessed June 1, 2016
   Google Scholar
• Franco J, Borrás J, Fernández R, et al. Guía para la prescripción y visado de antidiabéticos. Valencia, Spain: Instituto medico valenciano; 2016. http://www.imeval.org/pdf/Antidiabeticos_version_abril_2016.pdf. Accessed June 1, 2016
   Google Scholar
• Torre E, Tejedor F, Menéndez S, Núñez-Cortés J, García A. Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la dibabetes tipo 2. Atención Primaria 2011;43:202.e1-202.e9
   Google Scholar
• Rosensotck J, Guerci B, Hanefeld M, et al. Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 trial. Diabetes Care;39:1318-28
   PubMed Web of Science ®Google Scholar
• Horton E, Silberman C, Davis K, et al. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabets receiving incretin therapies or insulin in a large cohort database. Diabetes Care 2010;33:1759-65
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL-F1). U.S.: ClinicalTrials gov; 2016. https://clinicaltrials.gov/ct2/show/NCT00763451?term=Getgoal+F1&rank = 1. Accessed June 1, 2016
   Google Scholar
• Clinicaltrials.gov. GLP-1 receptor agonist lixisenatide (morning or evening) in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL-M). U.S.: ClinicalTrials gov; 2016. https://clinicaltrials.gov/ct2/show/NCT00712673?term=Getgoal+M&rank = 1. Accessed June 1, 2016
   Google Scholar
• Clinicaltrials.gov. GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes for glycemic control and safety evaluation, on top of basal insulin (GETGOAL-L). U.S.: ClinicalTrials gov; 2016. https://clinicaltrials.gov/ct2/show/NCT00715624?term=getgoal+L&rank = 2. Accessed June 1, 2016
   Google Scholar
• Clinicaltrials.gov. GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes for glycemic control and safety evaluation, on top of pioglitazone (GETGOAL-P). U.S.: ClinicalTrials gov; 2016. https://clinicaltrials.gov/ct2/show/NCT00763815?term=getgoal+P&rank = 1. Accessed June 1, 2016
   Google Scholar
• Clinicaltrials.gov. GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes for glycemic control and safety evaluation, on top of sulfonylurea (GETGOAL-S). U.S.: ClinicalTrials gov; 2016. https://clinicaltrials.gov/ct2/show/NCT00713830?term=getgoal+S&rank = 1. Accessed June 1, 2016
   Google Scholar
• Clinicaltrials.gov. GLP-1 receptor agonist lixisenatide versus exenatide in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL-X). U.S.: ClinicalTrials gov; 2016. https://clinicaltrials.gov/ct2/show/NCT00707031?term=GetGoal+X&rank = 1. Accessed June 1, 2016
   Google Scholar
• Wallis S. Binomial confidence intervals and contingency tests: mathematical fundamentals and the evaluation of alternative methods. J Quant Linguist 2013;20:178-208
   Web of Science ®Google Scholar
• Bank of England. Statistical Interactive Database - daily spot exchange rates against Sterling. BoE; 2016. http://www.bankofengland.co.uk/boeapps/iadb/Rates.asp. Accessed June 15, 2016
   Google Scholar
• British National Formulary. Lixisenatide. BNF; 2016. https://www.medicinescomplete.com/mc/bnf/current/DMD21941511000001102.htm?q=lyxumia&t=search&ss=text&tot = 3&p=1#DMD21941511000001102. Accessed May 1, 2016
   Google Scholar
• Agenzia Italiana Del Farmaco. Lyxumia; Determina 20 novembre 2013. Italy: Gazzetta Ufficiale; 2013. http://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta = 2013-11-28&atto.codiceRedazionale = 13A09598&elenco30giorni=false. Accessed June 1, 2016
   Google Scholar
• Consejo general de colegios oficiales de farmaceuticos. BotPlus 2.0. Spain: BotPlus; 2013. https://botplusweb.portalfarma.com/. Accessed June 1, 2016
   Google Scholar
• British National Formulary. Insulin Glargine. U.K.: BNF; 2016. https://www.medicinescomplete.com/mc/bnf/current/DMD11933011000001106.htm?q=lantus&t=search&ss=text&tot = 5&p=3#DMD11933011000001106. Accessed May 1, 2016
   Google Scholar
• Agenzia Italiana Del Farmaco. Insulina glargine; Determinazione 4 luglio 2007. Italy: Gazzetta Ufficiale; 2007. http://www.gazzettaufficiale.it/eli/id/2007/07/18/07A06229/sg. Accessed June 1, 2016
   Google Scholar
• British National Formulary. Insulin Glulisine. U.K.: BNF; 2016. https://www.medicinescomplete.com/mc/bnf/current/DMD9528311000001103.htm?q=apidra&t=search&ss=text&tot = 5&p=2#DMD9528311000001103. Accessed June 1, 2016
   Google Scholar
• Agenzia Italiana Del Farmaco. Insulina lispro; Determinazione 5 agosto 2005. Italy: Gazzetta Ufficiale; 2005. http://www.gazzettaufficiale.it/eli/id/2005/08/24/05A08323/sg;jsessionid=d9KzJ+bkLRv8Om3mFxZAGw__.ntc-as2-guri2b. Accessed June 1, 2016
   Google Scholar
• British National Formulary. Metformin Hydrochloride. U.K.: BNF; 2016. https://www.medicinescomplete.com/mc/bnf/current/PHP4161-metformin-hydrochloride.htm?q=metformin&t=search&ss=text&tot = 119&p=2#PHP58895-prescribing-and-dispensing-information. Accessed June 1, 2016
   Google Scholar
• Agenzia Italiana Del Farmaco. Classe A Principio Attivo. Italy: Agenzia Italiana Del Farmaco; 2017 http://www.agenziafarmaco.gov.it/it/content/tabelle-farmaci-di-classe-e-h-al-15122014-27012015
   Google Scholar
• NHS. NHS Electronic Drug Tariff; Part IXA Appliances. U.K.: NHS; 2016. http://www.drugtariff.nhsbsa.nhs.uk/#/00315892-DC/DC00315235/Part IXA-Appliances. Accessed May 1, 2016
   Google Scholar
• Admministrazione Transparente. Dispositivi primo semestre. Italy: Admministrazione Transparente; 2014. http://www.aogarbagnate.lombardia.it/SalviniWEB/AmministrazioneTrasparente/DisposizioniGenerali/Dispositivi-primo-semestre-2014.pdf. Accessed June 1, 2016
   Google Scholar
• MIMS. BD Micro-Fine + Pen Needles. U.K.: MIMS; 2016. http://www.mims.co.uk/drugs/diabetes/diagnostic-tests-and-appliances/bd-micro-fine-pen-needles. Accessed May 1, 2016
   Google Scholar
• MIMS. BGStar Test Strip. U.K.: MIMS; 2016. http://www.mims.co.uk/drugs/diabetes/diagnostic-tests-and-appliances/bgstar-test-strip. Accessed May 1, 2016
   Google Scholar
• Regione del Veneto. Prescrizione e dispensazione dispositivi per diabetic. Venezia, Italy: Regione del Veneto; 2016. https://www.regione.veneto.it/web/sanita/prescrizione-e-dispensazione-dispositivi-per-diabetici. Accessed June 1, 2016
   Google Scholar
• Bender R. Calculating confidence intervals for the number needed to treat. Contr Clin Trials 2016;22:102-10
   Google Scholar
• Ferrario M, Lizán L, Montagnoli R, et al. Liraglutide vs sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: short-term cost-per-controlled patient in Italy. Primary Care Diabetes 2016;10:220-6
   PubMed Web of Science ®Google Scholar
• Skovgaard R, Ploug U, Hunt B, et al. Evaluating the cost of bringing people with type 2 diabetes mellitus to multiple targets of treatment in Canada. Clin Ther 2015;37:1677-88
   PubMed Web of Science ®Google Scholar
• Langer J, Hunt B, Valentine W. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Spec Pharm 2013;19:237-46
   PubMed Web of Science ®Google Scholar